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Abstract
More and more targeted agents become available for B cell malignancies with increasing precision and potency.
The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of
chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. More selective BTK
inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel
irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This
review summarized the preclinical research and clinical data of acalabrutinib.
Background
New CD20 monoclonal antibodies and bispecific anti-
bodies are providing more treatment options with in-
creasing precision and potency for hematological
malignancies [1–7]. Even though chronic lymphocytic
leukemia (CLL) remains incurable at this time, more and
more treatment options are bringing clinical benefits to
patients with longer duration of response and less toxic-
ities commonly seen with conventional chemotherapeu-
tic agents [1, 8–11]. Bruton’s tyrosine kinase (BTK) is an
essential kinase in the B cell receptor (BCR) signaling
pathway and a driving force for CLL and other B cell
malignancies [12–14]. The first-in-class BTK inhibitor,
ibrutinib, has been in clinical use for the treatment of
chronic lymphocytic leukemia (CLL), mantle cell lymph-
oma, and Waldenstrom’s macroglobulinemia [11, 13,
15–17]. However, ibrutinib has untoward effects, such as
bleeding, rash, and atrial fibrillation, which could be
partly due to the bystander effects on targets other than
BTK [10, 13, 15, 17, 18]. Therefore, more selective BTK
inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-
292) are being explored [19–23]. Acalabrutinib, also
known as ACP-196, is a novel irreversible second-
generation BTK inhibitor that was rationally designed to
be more potent and selective than ibrutinib [19, 24–28].
This review summarized the preclinical research and
clinical data of acalabrutinib.
Mechanism of action and properties of acalabrutinib
Acalabrutinib binds covalently to Cys481 with improved
selectivity and in vivo target coverage compared to ibru-
tinib and CC-292 in CLL patients [19, 20, 26]. In the
in vitro signaling assay on primary human CLL cells,
acalabrutinib inhibited tyrosine phosphorylation of
downstream targets of ERK, IKB, and AKT [24]. Acalab-
rutinib demonstrated higher selectivity for BTK with
IC50 determinations on nine kinases with a cysteine resi-
due in the same position as BTK [19]. Importantly, unlike
ibrutinib, acalabrutinib did not inhibit EGFR, ITK, or TEC
[19, 24]. In the in vitro assays reported in the supplemen-
tal data, it was clearly demonstrated that, unlike ibrutinib,
acalabrutinib had no effect on EGFR phosphorylation on
tyrosine residues y1068 and y1173. At 1000 nM, ibrutinib
completely suppressed Tec activity, though 1000 nM aca-
labrutinib had minimal activity on Tec [24]. Compared
with ibrutinib, acalabrutinib has much higher IC50 (>1000
nM) or virtually no inhibition on kinase activities of ITK,
EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK,
LCK, LYN, SRC, and YES1 [24].
The differential effects of acalabrutinib on primary
CLL cells, T cells, NK cells, and epithelial cells were
studied by signaling and functional assays. Acalabrutinib
inhibited purified BTK with an IC50 of 3 nM and EC50
of 8 nM in a human whole-blood CD69 B cell activation
assay [19]. Acalabrutinib was shown to have improved
target specificity over ibrutinib with 323-, 94-, 19-, and
9-fold selectivity over the other TEC kinase family mem-
bers (ITK, TXK, BMX, and TEC, respectively) and no
activity against EGFR.
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The effects of ibrutinib and acalabrutinib on platelets
were also compared in an in vivo VWFHA1 mouse
thrombosis model. The platelets from patients treated
with ibrutinib 420 mg once per day or acalabrutinib
100 mg twice per day were assessed for thrombus for-
mation at injured arterioles of the mice. The thrombus
sizes from acalabrutinib-treated platelets were comparable
to those of healthy controls, whereas thrombus formation
was clearly inhibited in ibrutinib-treated platelets. These
data suggest that acalabrutinib, unlike ibrutinib, is more
selective for inhibiting BTK and has virtually no inhibition
of platelet activity [24].
There data clearly suggest that acalabrutinib is a more
selective and potent second-generation BTK inhibitor.
Acalabrutinib (ACP-196) in preclinical research
Acalabrutinib was evaluated in several animal models of
B cell non-Hodgkin lymphoma (NHL). These studies
provided preclinical in vivo data necessary to move aca-
labrutinib into human trials. In a study of canine model
of B cell NHL, 12 dogs with B cell NHL were orally ad-
ministered acalabrutinib at escalating dosages of 2.5 mg/
kg every 24 h (6 dogs), 5 mg/kg every 24 h (5 dogs), or
10 mg/kg every 12 h (1 dog). As a result, 3 dogs
achieved a partial remission (PR), 3 dogs had stable dis-
ease (SD), whereas the remaining 6 dogs had progression
of disease (PD). This study therefore showed that acalab-
rutinib has single agent biologic activity in a spontan-
eous large animal model of NHL [25].
The in vivo effects of acalabrutinib against CLL cells
were demonstrated in the NSG mouse model with xeno-
grafts of human CLL [28]. Acalabrutinib significantly
inhibited proliferation of human CLL cells in the spleens
of NSG mice at all dose levels, as measured for the ex-
pression of Ki67 (P = 0.002). Tumor burden decreased
with the treatment of acalabrutinib in a dose-dependent
manner. Acalabrutinib inhibited BCR signaling by re-
duced phosphorylation of PLCγ2. Acalabrutinib transi-
ently increased CLL cell counts in the peripheral blood.
Therefore, the novel BTK inhibitor acalabrutinib shows
in vivo efficacy against human CLL cells xenografted to
the NSG mouse model.
Two murine models were used in another in vivo study
[29, 30]. In the TCL1 adoptive transfer model, acalabrutinib
inhibited BCR signaling by decreased autophosphorylation
of BTK and reduction in surface expression of the BCR ac-
tivation markers CD86 and CD69. Most interestingly, aca-
labrutinib treatment increased survival significantly over
mice receiving vehicle (median 81 vs 59 days, P = 0.02).
The second murine model was the NSG xenograft model.
Acalabrutinib treatment significantly decreased the phos-
phorylation of PLCγ2 and ERK (P = 0.02), reduced tumor
cell proliferation (P = 0.02), and tumor burden (P = 0.04).
Table 1 Acalabrutinib (ACP-196) for hematological malignancies
Agents Diseases Phase NCT
ACP-196
Dexamethasone
MM Phase 1 NCT02211014
ACP-196 ABC DLBCL Phase 1 NCT02112526
ACP-196
Rituximab (IV)
FL Phase 1 NCT02180711
ACP-196
Obinutuzumab
CLL, SLL, PLL Phase 1 NCT02296918
ACP-196
ACP-319
CLL Phase 1 NCT02157324
ACP-196
ACP-319
NHL, MM, B-All Phase 1/2 NCT02328014
ACP-196 WM Phase 1/2 NCT02180724
ACP-196 CLL, SLL, RS, PLL Phase 1/2 NCT02029443
ACP-196
Pembrolizumab
NHL, MM, HL, CLL, RS, WM, Myelofibrosis Phase 1/2 NCT02362035
ACP-196 CLL, SLL Phase 2 NCT02337829




CLL Phase 3 NCT02475681
ACP-196
Ibrutinib
CLL Phase 3 NCT02477696
NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma, MCL mantle cell lymphoma, FL follicular lymphoma, ABC DLBCL activated B cell
diffuse large B cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma, WM Waldenstrom’s macroglobulinemia, RS Richter’s syndrome,
PLL prolymphocytic leukemia
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Acalabrutinib was shown to be a potent inhibitor of BTK
in both murine models of human CLL [29].
Acalabrutinib in clinical development
To further assess the safety, efficacy, pharmacokinetics,
and pharmacodynamics of acalabrutinib in human CLL,
a phase 1/2, multicenter, open-label, and dose-escalation
clinical trial has been ongoing (NCT02029443). In the
latest report, 61 patients with relapsed CLL were en-
rolled [24]. These patients had received a median of
three prior therapies for CLL. Among them, 31 % were
positive for 17p13.1 deletion and 75 % had IGvH unmu-
tated. In the phase 1 portion of this study, patients were
treated with acalabrutinib at an increasing dose of 100
to 400 mg once daily. In the phase 2 expansion portion,
100 mg twice daily was given. After a median follow-up
of 14.3 months (range 0.5–20), the overall response rate
(ORR) was 95 %, with 85 % PR, 10 % PR with lymphocy-
tosis. The remaining 5 % of patients were reported to
have SD. The ORR was 100 % in those patients with
chromosome 17p13.1 deletion. Headache, diarrhea, and
weight gain were the most common adverse events.
There were no dose-limiting toxicities observed in the
phase I portion of the trial. There was no Richter’s trans-
formation and no cases of atrial fibrillation have been re-
ported to date [24]. The preclinical data from this report
confirmed that acalabrutinib is a highly selective BTK
inhibitor. It does not inhibit TEC kinase and platelet ag-
gregation which would be a preferred advantage over
ibrutinib and would have reduced bleeding risk. Acalab-
rutinib does not inhibit EGFR, thus could reduce the ad-
verse events on skin rash and severe diarrhea. Transient
headaches were reported to be a common adverse event
from acalabrutinib and appeared to be more frequently
seen than in those patients on ibrutinib from historical
data. More patients and longer follow-up from this study
are needed to ascertain these potential advantages and
disadvantages. In addition, direct comparison of acalab-
rutinib with ibrutinib will be the only way to confirm
the advantages and disadvantages of these agents.
At this time, a phase 3 study (NCT02477696) has
commenced in which acalabrutinib is being compared
with ibrutinib in high-risk patients with relapsed CLL.
Studies in treatment-naïve CLL are also being done
(Table 1).
Conclusion and future directions
Acalabrutinib is a more selective irreversible second-
generation BTK inhibitor. It has improved target specifi-
city and enhanced potency for BTK due to reduced off-
target activity on EGFR, TEC, etc., which may lead to
less untoward effects and toxicities. More patients and
longer follow-up from the ongoing phase I/II clinical
study are needed to ascertain these potential advantages.
Multiple trials on other hematological malignancies and
solid tumors are underway (Tables 1 and 2). Combin-
ation of acalabrutinib and other agents (new CD19 and
CD20 antibodies, BCL-2 inhibitors, PI3 kinase inhibi-
tors, ALK inhibitors, etc.) for B cell malignancies will
likely further increase response rate and duration of re-
sponse [1, 8, 31–37] (Table 1). It will also be interesting
to see whether resistance mechanisms will be differ-
ent from those for ibrutinib. Finally, additional select-
ive BTK inhibitors, i.e., ONO/GS-4059 and BGB-
3111, are under active clinical development [21–23].
More options of treatment may become available for
B cell malignancies.
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Table 2 Acalabrutinib (ACP-196) for solid tumors
Agents Diseases Phase NCT
ACP-196 Glioblastoma multiforme Phase 1/2 NCT02586857
ACP-196
Pembrolizumab
Urothelial carcinoma Phase 2 NCT02351739
ACP-196
Pembrolizumab








Ovarian cancer Phase 2 NCT02537444
ACP-196
Pembrolizumab




Pancreatic cancer Phase 2 NCT02570711
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